These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15885609)

  • 21. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome.
    Cuisset T; Frere C; Quilici J; Morange PE; Saut N; Lambert M; Camoin L; Vague IJ; Bonnet JL; Alessi MC
    Thromb Res; 2007; 120(6):893-9. PubMed ID: 17337040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
    Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
    J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification.
    Neubauer H; Lask S; Engelhardt A; Mügge A
    Thromb Haemost; 2008 Feb; 99(2):357-62. PubMed ID: 18278186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients.
    Kotzailias N; Elwischger K; Sycha T; Rinner W; Quehenberger P; Auff E; Müller C
    J Stroke Cerebrovasc Dis; 2007; 16(5):199-202. PubMed ID: 17845916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of VerifyNow P2Y12 assay accuracy in evaluating clopidogrel-induced platelet inhibition.
    Lordkipanidzé M; Pharand C; Nguyen TA; Schampaert E; Diodati JG
    Ther Drug Monit; 2008 Jun; 30(3):372-8. PubMed ID: 18520610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: a historical perspective.
    Packham MA; Mustard JF
    Semin Thromb Hemost; 2005 Apr; 31(2):129-38. PubMed ID: 15852216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
    Storey RF; May JA; Heptinstall S
    Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
    Storey RF; Husted S; Harrington RA; Heptinstall S; Wilcox RG; Peters G; Wickens M; Emanuelsson H; Gurbel P; Grande P; Cannon CP
    J Am Coll Cardiol; 2007 Nov; 50(19):1852-6. PubMed ID: 17980251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAR-1 genotype influences platelet aggregation and procoagulant responses in patients with coronary artery disease prior to and during clopidogrel therapy.
    Smith SM; Judge HM; Peters G; Armstrong M; Dupont A; Gaussem P; Storey RF
    Platelets; 2005 Sep; 16(6):340-5. PubMed ID: 16194864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study.
    Angiolillo DJ; Shoemaker SB; Desai B; Yuan H; Charlton RK; Bernardo E; Zenni MM; Guzman LA; Bass TA; Costa MA
    Circulation; 2007 Feb; 115(6):708-16. PubMed ID: 17261652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Macaya C
    Am J Cardiol; 2006 Jan; 97(1):38-43. PubMed ID: 16377281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aprotinin reduces the antiplatelet effect of clopidogrel.
    Lindvall G; Sartipy U; Bjessmo S; Svenarud P; Lindvall B; van der Linden J
    Interact Cardiovasc Thorac Surg; 2009 Aug; 9(2):178-81. PubMed ID: 19477870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
    Angiolillo DJ; Fernandez-Ortiz A; Bernardo E; Ramírez C; Cavallari U; Trabetti E; Sabaté M; Jimenez-Quevedo P; Hernández R; Moreno R; Escaned J; Alfonso F; Bañuelos C; Costa MA; Bass TA; Pignatti PF; Macaya C
    Thromb Res; 2005; 116(6):491-7. PubMed ID: 16181985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of platelet antigen polymorphism on platelet inhibition by aspirin, clopidogrel, or their combination.
    Cooke GE; Liu-Stratton Y; Ferketich AK; Moeschberger ML; Frid DJ; Magorien RD; Bray PF; Binkley PF; Goldschmidt-Clermont PJ
    J Am Coll Cardiol; 2006 Feb; 47(3):541-6. PubMed ID: 16458133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy.
    Saraf S; Wellsted D; Sharma S; Gorog DA
    Thromb Res; 2009 Sep; 124(4):447-51. PubMed ID: 19476973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
    Yang J; Hua WY; Wang FX; Wang ZY; Wang X
    Bioorg Med Chem; 2004 Dec; 12(24):6547-57. PubMed ID: 15556771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
    Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
    Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel resistance.
    Oqueli E; Hiscock M; Dick R
    Heart Lung Circ; 2007; 16 Suppl 3():S17-28. PubMed ID: 17611155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.